JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 19 February 2001. doi:10.1083/jcb.152.4.741
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 302K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Webb, D. J.
Right arrow Articles by Gonias, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Webb, D. J.
Right arrow Articles by Gonias, S. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2001//741 $5.00
The Journal of Cell Biology, Volume 152, Number 4, , 2001 741-752


Original Article

Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes Mcf-7 Cell Growth



Donna J. Webba, Keena S. Thomasa, and Steven L. Goniasa

a Department of Pathology, and Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia 22908
Departments of Pathology, Biochemistry, and Molecular Genetics, Box 800214, Charlottesville, VA 22908.(804) 924-9192; Fax: (804) 982-0283; E-mail: slg2t@virginia.edu

Plasminogen activator inhibitor 1 (PAI-1) is a major inhibitor of urokinase-type plasminogen activator (uPA). In this study, we explored the role of PAI-1 in cell signaling. In MCF-7 cells, PAI-1 did not directly activate the mitogen-activated protein (MAP) kinases, extracellular signal–regulated kinase (ERK) 1 and ERK2, but instead altered the response to uPA so that ERK phosphorylation was sustained. This effect required the cooperative function of uPAR and the very low density lipoprotein receptor (VLDLr). When MCF-7 cells were treated with uPA–PAI-1 complex in the presence of the VLDLr antagonist, receptor-associated protein, or with uPA–PAI-1R76E complex, which binds to the VLDLr with greatly decreased affinity, transient ERK phosphorylation (<5 min) was observed, mimicking the uPA response. ERK phosphorylation was not induced by tissue-type plasminogen activator–PAI-1 complex or by uPA–PAI-1 complex in the presence of antibodies that block uPA binding to uPAR. uPA–PAI-1 complex induced tyrosine phosphorylation of focal adhesion kinase and Shc and sustained association of Sos with Shc, whereas uPA caused transient association of Sos with Shc.

By sustaining ERK phosphorylation, PAI-1 converted uPA into an MCF-7 cell mitogen. This activity was blocked by receptor-associated protein and not observed with uPA–PAI-1R76E complex, demonstrating the importance of the VLDLr. uPA promoted the growth of other cells in which ERK phosphorylation was sustained, including β3 integrin overexpressing MCF-7 cells and HT 1080 cells. The MEK inhibitor, PD098059, blocked the growth-promoting activity of uPA and uPA–PAI-1 complex in these cells. Our results demonstrate that PAI-1 may regulate uPA-initiated cell signaling by a mechanism that requires VLDLr recruitment. The kinetics of ERK phosphorylation in response to uPAR ligation determine the function of uPA and uPA–PAI-1 complex as growth promoters.

Key Words: urokinase-type plasminogen activator • plasminogen activator inhibitor 1 • urokinase receptor • VLDL receptor • extracellular signal–regulated kinase



© 2001 The Rockefeller University Press

Abbreviations used in this paper: DIP, diisopropyl phospho; ERK, extracellular signal–regulated kinase; FAK, focal adhesion kinase; GST, glutathione-S-transferase; LDL, low density lipoprotein; MAP, mitogen-activated protein; MLCK, myosin light chain kinase; PAI, plasminogen activator inhibitor; RAP, receptor-associated protein; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; uPAR, uPA receptor; VLDL, very low density lipoprotein; VLDLr, VLDL receptor.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents